Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | CD40 | P25942 | 2/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.34 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9616877 | 1.00 | MMP2 (0.39) | MMP2SLC15A2TERTCD40DPP8 | |
| SCHEMBL9200315 | 1.00 | MMP2 (0.39) | MMP2SLC15A2TERTCD40DPP8 | |
| SCHEMBL29484171 | 0.97 | SLC15A2 (0.41) | MMP2SLC15A2TERTCD40PSMB1 | |
| SCHEMBL6116135 | 0.94 | SLC15A2 (0.41) | MMP2SLC15A2TERTCD40PSMB1 | |
| SCHEMBL6116125 | 0.94 | SLC15A2 (0.41) | MMP2SLC15A2TERTCD40PSMB1 | |
| SCHEMBL3357251 | 0.93 | SLC15A2 (0.42) | MMP2SLC15A2TERTCD40PSMB1 | |
| SCHEMBL3357272 | 0.93 | SLC15A2 (0.42) | MMP2SLC15A2TERTCD40PSMB1 | |
| SCHEMBL8431409 | 0.92 | PSMB1 (0.39) | MMP2SLC15A2PSMB1PSMB8PSMB9 | |
| SCHEMBL7160634 | 0.92 | MMP2 (0.37) | MMP2SLC15A2TERTCD40DPP8 | |
| SCHEMBL7160638 | 0.92 | MMP2 (0.37) | MMP2SLC15A2TERTCD40DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747264-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | University of Reading (GB) | 2026-05-27 | — | — | EP | claimed |
| WO-2025037123-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | UNIVERSITY OF READING (GB) | 2025-02-20 | — | — | WO | claimed |
| US-12128110-B2 | Transglutaminase conjugation method and linker | PAUL SCHERRER INSTITUT (CH) | 2024-10-29 | — | — | US | claimed |
| EP-0489860-B1 | METHODS AND COMPOSITIONS FOR HEALING ULCERS | PROCYTE CORP (US) | 1995-08-02 | — | — | EP | claimed |
| US-5162329-A | Fungicides | BASF AKTIENGESELLSCHAFT (DE) | 1992-11-10 | — | — | US | claimed |
| US-5145838-A | Peptide derivatives | PROCYTE CORPORATION (US) | 1992-09-08 | — | — | US | claimed |
| EP-0489860-A1 | METHODS AND COMPOSITIONS FOR HEALING ULCERS. | PROCYTE CORP (US) | 1992-06-17 | — | — | EP | claimed |
| US-5023237-A | Using oligopeptide containing glycine, histidine, and lysine | PROCYTE CORPORATION (US) | 1991-06-11 | — | — | US | claimed |
| WO-1991003488-A1 | METHODS AND COMPOSITIONS FOR HEALING ULCERS | PROCYTE CORPORATION (US) | 1991-03-21 | — | — | WO | claimed |
| US-12472226-B2 | Cell-permeable peptide | AMANO SHIGERU (JP) | 2025-11-18 | — | — | US | disclosed |
| US-20250161479-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | PAUL SCHERRER INSTITUT (CH) | 2025-05-22 | — | — | US | disclosed |
| US-12128110-B2 | Transglutaminase conjugation method and linker | PAUL SCHERRER INSTITUT (CH) | 2024-10-29 | — | — | US | disclosed |
| US-20240350656-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | PAUL SCHERRER INSTITUT (CH) | 2024-10-24 | — | — | US | disclosed |
| CN-118126119-B | Tretinoin polypeptide derivative and preparation method and application thereof | 荷本世新(北京)生物科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-1991003488-A1 | METHODS AND COMPOSITIONS FOR HEALING ULCERS | PROCYTE CORPORATION (US) | 1991-03-21 | — | — | WO | disclosed |
| WO-1991003488-A1 | METHODS AND COMPOSITIONS FOR HEALING ULCERS | PROCYTE CORPORATION (US) | 1991-03-21 | — | — | WO | disclosed |
| US-4866121-A | B cell differentiating peptides and conjugates thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-09-12 | — | — | US | disclosed |
| US-4783442-A | B-cell differentiating peptides | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
| EP-0190048-A2 | Bursopoietin | ORTHO PHARMACEUTICAL CORPORATION (US) | 1986-08-06 | — | — | EP | disclosed |
| US-4584284-A | OLIGOPEPTIDE OF LYSINE, HISTIDINE AND GLYCINE-PRODUCING ANTIBODIES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1986-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161479-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | TGM3, TGM2, TGM1 | MMP2 1283/4885SLC15A2 1531/4885TERT 3183/4885 |
| US-12128110-B2 | Transglutaminase conjugation method and linker | TGM3, TGM2, TGM1 | MMP2 1392/4885SLC15A2 1512/4885TERT 3290/4885 |
| US-20240350656-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | TGM3, TGM2, TGM1 | MMP2 1327/4885SLC15A2 1489/4885TERT 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.